Zinzino announced its interim report for the third quarter of 2025. Revenue during the quarter was $82 million, representing 47% growth when compared to the same quarter last year. Gross profit was $29 million with a gross profit margin of 35.4%. EBITDA during the quarter was $11.5 million with an EBITDA margin of 14%. The company’s acquisition of Zurvita and stronger gross profit has supported improvements in its EBITDA margin. Net profit was $9.4 million with cash flow from operating activities of $14.3 million. During the quarter, the health segment made up 93% of total sales.
Results for the first nine months of 2025 show total revenue of $242 million with a gross profit of $78.8 million. EBITDA was $28.2 million with an EBITDA margin of 11.6%. Net earnings per share during this period was $0.60. Cash and cash equivalents at the end of September 2025 totaled $55.7 million.
The company has made a total of seven acquisitions so far this year, including Bodē Pro, Truvy, Sanki and Xion, which were made during the quarter or soon after the end of the quarter. The company stated it is actively looking for new companies to acquire as it continues to increase its distribution power, improve access to raw materials, invest in AI and develop its technology platform.
“We are focusing on meeting all our financial and strategic goals and balance short-term and long-term focus while continuing to work on larger plans and strategies for the coming years,” said Dag Bergheim Petterson, Zinzino CEO. “There are some clear areas that we measure ourselves against and where our focus is to develop our sales on a global scale in both our existing markets and to open new ones. We are working on further developing our existing product portfolio while developing new products and services. We recently launched a brand-new test that we call the Gut Health Test. It is many years of scientific studies and research that have now been launched and we are proud to say that over 60,000 tests were sold in less than a month. This further increases our brand awareness and publicity, as well as helps many new customers to better preventive health. In addition, we are building a database that we can utilize for future research and develop even better products going forward, completely based on data and science.”
Zinzino offered an outlook for 2025-2027 that showed an average sales growth of “at least” 20% with an operating margin before depreciation of more than 10%.
